Hansoh Pharma Deal History & Licensing Activity
Hansoh Pharma is a large pharma headquartered in China. Over the past three years, Hansoh Pharma has been involved in 13 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Hansoh Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Hansoh Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| risvutatug rezetecan (ris-rez) / HS-20093 | GSK | ADC | Phase 3 | license | Jul 10, 2026 |
| HS-10535 | Merck | Small Molecules | Unknown | license | Jul 1, 2026 |
| mRNAi GOLD platform (siRNA therapies, 3 targets) | Hansoh Pharmaceutical | Oligonucleotides | Unknown | option | Jun 23, 2026 |
| Undisclosed | Roche | Small Molecules | Phase 2 | license | Oct 16, 2025 |
Hansoh Pharma Pipeline Focus
Therapeutic areas and modalities where Hansoh Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Hansoh Pharma Strategic Signals
Key indicators of Hansoh Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Hansoh Pharma Clinical Pipeline
Hansoh Pharma has 50 active clinical trials across 5 development phases.
2
Phase 4
1
Not Applicable
36
Phase 1
4
Phase 2
7
Phase 3
See How Your Asset Matches Hansoh Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Hansoh Pharma Licensing & Deal Activity
Hansoh Pharma is a large pharma company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 13 deals over the past three years, Hansoh Pharma ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Hansoh Pharma include Solid Tumors (17 deals and trials), Oncology (8 deals and trials), Metabolic (8 deals and trials), and CNS Disorders (3 deals and trials). In terms of modality, Hansoh Pharma has shown particular interest in small molecules, adc, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hansoh Pharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Hansoh Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.